- Home
- VYGR vs TONX Comparison
VYGR vs TONX Comparison
Compare VYGR & TONX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- TONX
- Stock Information
- Founded
- VYGR 2013
- TONX N/A
- Country
- VYGR United States
- TONX United States
- Employees
- VYGR N/A
- TONX N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- TONX Other Consumer Services
- Sector
- VYGR Health Care
- TONX Consumer Discretionary
- Exchange
- VYGR Nasdaq
- TONX Nasdaq
- Market Cap
- VYGR 231.9M
- TONX 248.4M
- IPO Year
- VYGR 2015
- TONX N/A
- Fundamental
- Price
- VYGR $4.23
- TONX $3.28
- Analyst Decision
- VYGR Strong Buy
- TONX
- Analyst Count
- VYGR 7
- TONX 0
- Target Price
- VYGR $17.00
- TONX N/A
- AVG Volume (30 Days)
- VYGR 551.0K
- TONX 683.7K
- Earning Date
- VYGR 11-06-2025
- TONX 11-14-2025
- Dividend Yield
- VYGR N/A
- TONX N/A
- EPS Growth
- VYGR N/A
- TONX N/A
- EPS
- VYGR N/A
- TONX N/A
- Revenue
- VYGR $42,580,000.00
- TONX $4,279,000.00
- Revenue This Year
- VYGR N/A
- TONX $526.82
- Revenue Next Year
- VYGR $107.10
- TONX $45.45
- P/E Ratio
- VYGR N/A
- TONX N/A
- Revenue Growth
- VYGR N/A
- TONX 4095.10
- 52 Week Low
- VYGR $2.65
- TONX $3.01
- 52 Week High
- VYGR $7.44
- TONX $13.90
- Technical
- Relative Strength Index (RSI)
- VYGR 41.58
- TONX N/A
- Support Level
- VYGR $4.10
- TONX N/A
- Resistance Level
- VYGR $4.30
- TONX N/A
- Average True Range (ATR)
- VYGR 0.26
- TONX 0.00
- MACD
- VYGR -0.10
- TONX 0.00
- Stochastic Oscillator
- VYGR 20.89
- TONX 0.00
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About TONX TON Strategy Company Common Stock
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.